CGTX
Cognition Therapeutics Inc

3,929
Mkt Cap
$93.57M
Volume
100.00
52W High
$3.83
52W Low
$0.2223
PE Ratio
-2.23
CGTX Fundamentals
Price
$1.07
Prev Close
$1.06
Open
$1.06
50D MA
$1.45
Beta
1.49
Avg. Volume
1M
EPS (Annual)
-$0.855
P/B
2.56
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
FY2025 Earnings Forecast for CGTX Issued By Brookline Cap M
Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - Investment analysts at Brookline Cap M issued their FY2025 EPS estimates for Cognition Therapeutics in a research note issued to investors...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Cognition Therapeutics (NASDAQ:CGTX) Upgraded to Strong-Buy at Brookline Cap M
Brookline Cap M raised shares of Cognition Therapeutics to a "strong-buy" rating in a research report on Tuesday...
MarketBeat·3d ago
News Placeholder
Brookline Capital Management Predicts CGTX FY2025 Earnings
Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - Brookline Capital Management issued their FY2025 earnings estimates for shares of Cognition Therapeutics in a research report issued on...
MarketBeat·4d ago
News Placeholder
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) have earned an average rating of "Moderate Buy" from the five ratings firms that are currently covering the firm, MarketBeat...
MarketBeat·5d ago
News Placeholder
Cognition Therapeutics (NASDAQ:CGTX) Raised to "Strong-Buy" at Brookline Capital Management
Brookline Capital Management raised shares of Cognition Therapeutics to a "strong-buy" rating in a research report on Tuesday...
MarketBeat·5d ago
News Placeholder
DAVENPORT & Co LLC Makes New Investment in Cognition Therapeutics, Inc. $CGTX
DAVENPORT & Co LLC purchased a new stake in Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The fund purchased 2,689,336...
MarketBeat·2mo ago
News Placeholder
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five brokerages that are currently covering the firm...
MarketBeat·2mo ago
News Placeholder
Cognition Therapeutics (NASDAQ:CGTX) Earns "Buy" Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $3.00 price objective on shares of Cognition Therapeutics in a research report on Thursday...
MarketBeat·2mo ago
News Placeholder
Q1 Earnings Forecast for CGTX Issued By B. Riley
Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - Equities research analysts at B. Riley issued their Q1 2026 earnings per share estimates for Cognition Therapeutics in a report issued on...
MarketBeat·3mo ago
News Placeholder
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five brokerages that are covering the stock, MarketBeat.com reports...
MarketBeat·3mo ago
<
1
2
...
>

Latest CGTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.